Modification of the cardiovascular effects of L-dopa in anesthetized dogs by inhibitors of enzymes involved in catecholamine metabolism.
D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D001919:Bradycardia / Q000139:chemically induced; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D003408:Cresols / Q000494:pharmacology; D004295:Dihydroxyphenylalanine / Q000378:metabolism / Q000494:pharmacology*; D004285:Dogs; D004298:Dopamine / Q000378:metabolism; D005260:Female; D006339:Heart Rate / Q000187:drug effects*; D006834:Hydrazines / Q000494:pharmacology; D006973:Hypertension / Q000139:chemically induced; D007022:Hypotension / Q000139:chemically induced; D008297:Male; D008750:Methyldopa / Q000494:pharmacology; D008996:Monoamine Oxidase Inhibitors / Q000378:metabolism / Q000494:pharmacology*; D009638:Norepinephrine / Q000494:pharmacology; D013610:Tachycardia / Q000139:chemically induced; D013859:Thiocarbamates / Q000494:pharmacology
D003408:Cresols; D006834:Hydrazines; D008996:Monoamine Oxidase Inhibitors; D013859:Thiocarbamates; D000804:Angiotensin II; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D002262:Carboxy-Lyases; D004298:Dopamine; D009638:Norepinephrine